Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Article in English | IMSEAR | ID: sea-43846

ABSTRACT

OBJECTIVES: To determine the perinatal impacts of heroin and amphetamine on both mothers and infants. MATERIAL AND METHOD: This is a retrospective study on the influence of amphetamine and heroin on pregnant women and their newborn infants at King Chulalongkorn Memorial Hospital in Bangkok, Thailand, between January 1997 and December 2002. The medical and demographic data of both mothers and infants were evaluated. Comparison of the consistent drug effects of these 2 drugs on the mothers and infants were also performed RESULTS: Two hundred and eleven women were identified There were 178 (84.4%) and 33 (15.6%) women addicted to amphetamine and heroin respectively. Sixty one (28.9%) of them were polydrug users. There were more polydrug users among heroin addicts than amphetamine addicts, (43.7% vs 27.2%, p < 0.05). Poor obstetric history were noted in both groups of women including lack of prenatal care (74.9%), a high incidence of previous abortion (22.3%), positive HIV serology test (11.1%), pre-eclampsia (5.2%), infection (3.3%) and antepartum hemorrhage (1.9%). Drug intoxication was found in 11 amphetamine addicted mothers, whereas 2 heroin addicts developed withdrawal symptoms during intrapartum and postpartum periods. All infants were singleton. There was one stillbirth and 2 neonatal deaths. There was no statistical difference in terms of sex ratio, mean birth weight, gestational age, length, head circumference and Apgar score between the groups of amphetamine and heroin exposed infants. The incidence of prematurity, low birth weight, IUGR and microcephaly were not statistically different between both groups of infants. The overall incidence was 31.7%, 31.7%, 9.5% and 8.6% respectively. Congenital anomalies were found in 5 (2.8%) amphetamine exposed infants. Thirty one out of 33 heroin exposed infants (93.9%) and 4 out of 178 amphetamine exposed infants (2.2%) developed drug withdrawal symptoms with the mean onset of 21.5 +/- 16.5 hours and 10.3 +/- 7.5 hours respectively, p > 0.05. All heroin withdrawal infants were successfully treated with Phenobarbital with the mean duration of treatment of 23.7 +/- 11.5 days. None of the amphetamine withdrawal infants needed specific treatment. They recovered spontaneously within 6.0 +/- 5.3 days. Eighteen infants were left in an orphanage or under the custody of their relatives. CONCLUSION: Amphetamine or heroin use during pregnancy can cause many serious adverse effects on both mothers and infants. The findings in the present study are consistent with previous reports, although they seemed to be more common and severe. Increasing awareness and improving understanding of drug abuse in the medical, legal and social aspects are needed in order to reduce these impacts.


Subject(s)
Abnormalities, Drug-Induced/epidemiology , Adult , Amphetamine-Related Disorders/complications , Female , Heroin Dependence/complications , Humans , Infant Welfare , Infant, Low Birth Weight , Infant, Newborn , Infant, Premature , Male , Maternal Welfare , Maternal-Fetal Exchange , Neonatal Abstinence Syndrome/epidemiology , Perinatal Care , Pregnancy , Pregnancy Complications/chemically induced , Pregnancy Outcome , Retrospective Studies , Risk Factors , Thailand/epidemiology
2.
Article in English | IMSEAR | ID: sea-41308

ABSTRACT

OBJECTIVES: To determine the antibody response of hepatitis B immunization begun at birth in HIV-1 exposed infants. DESIGN: Prospective, clinical trial. SITE: King Chulalongkorn Memorial Hospital, Bangkok, Thailand. MATERIAL AND METHOD: Seventy six infants born to HIV-1 seropositive mothers, who were not hepatitis B carriers, received three 10 microgram doses of recombinant DNA hepatitis B vaccine (Engerix B, Smith Kline, Belgium) in a 0, 1 and 6 month schedule. The first dose was given at birth. Serum hepatitis B surface antibody (Anti -HBs) was measured at age 3, 9 and 12 months. Anti-HBs levels were determined by enzyme-linked immunoassay using the commercial kits (AUSAB EIA diagnostic kits, Abbott Laboratories, Chicago, USA) Antibody titer > or = 10 mIU/ml was defined as seroconversion. HIV infection was diagnosed by a positive test of HIV antibody at age > or = 18 months and/or by positive test of HIV polymerase chain reaction at age > or = 3 months. RESULTS: There were 14 HIV-1 infected (group 1) and 62 HIV-1 non infected (group 2) infants enrolled in this study. Anti-HBs titers of group 1 infants were significantly lower than those of groups 2 infants at both 3 and 6 months after the 3rd dose of vaccine, (Mann Whitney U test, p=0.019 and 0.001 respectively). Ten infants in group 1 and 57 infants in group 2 had anti-HBs titer > or = 10 mIU/ml. Their peak antibody titers were also noted at both 3 and 6 months after the 3rd dose of vaccine. Seroconversion rates were 71.4 per cent and 91.9 per cent in group 1 and 2 infants respectively, (p<0.05). Among the infants who had blood tests performed at age 12 months or 6 months after the 3rd dose of vaccine, anti-HBs titers declined in approximately 50 per cent of both groups of infants. There was a significantly higher percentage of seroconverters in group 1 who lost their protective titers than those in group 2, (p<0.001). CONCLUSION: The results in this study suggested that HIV-1 infected infants have poor antibody response to hepatitis B immunization and the protection was less durable. A fourth dose of vaccine at 6 months after the 3rd dose may be necessary.


Subject(s)
Female , HIV Infections/complications , HIV-1 , Hepatitis B/complications , Hepatitis B Antibodies/blood , Hepatitis B Vaccines/administration & dosage , Humans , Infant, Newborn , Male , Vaccines, Synthetic/administration & dosage
3.
Article in English | IMSEAR | ID: sea-40657

ABSTRACT

The evaporation rate (ER) from the skin was measured in 40 jaundiced preterm infants born at less than or equal to 34 weeks of gestation. The baseline measurements were executed in both the right and left side in 3 positions: upper arm, back and lower leg. The patients were randomly recruited to a treatment or a control group. The treatment group received 3.0 ml of clear topical ointment just before phototherapy. Conventional phototherapy was placed above the incubators in both groups. ER and ambient skin temperature were measured at the same point at 30 minutes and 5 hours during phototherapy. In the control group, ER was increased by 8.0 per cent (P value = 0.01) and 14.5 per cent (P value < 0.001) at 30 minutes and 5 hours during phototherapy, respectively. In the treatment group, clear topical ointment decreased ER by 19.2 per cent (P value < 0.001) and 13.2 per cent (P value = 0.003) at 30 minutes and 5 hours during phototherapy, respectively. Ambient skin temperature during phototherapy was increased significantly (P < 0.01) in both groups. Serum microbilirubin difference of pre and post phototherapy at 24 hours of phototherapy between the 2 groups was not significantly different (P = 0.38). The authors concluded that conventional phototherapy, in premature infants nursed in an incubator, increased transepidermal water loss (TEWL) significantly and the application of clear topical ointment on the skin of jaundiced preterm infants receiving conventional phototherapy in incubators reduce TEWL significantly, without effect on serum microbilirubin.


Subject(s)
Administration, Topical , Combined Modality Therapy , Dehydration/etiology , Female , Follow-Up Studies , Humans , Infant, Newborn , Infant, Premature, Diseases/diagnosis , Jaundice, Neonatal/diagnosis , Male , Ointments/administration & dosage , Phototherapy/adverse effects , Probability , Reference Values , Skin Temperature/drug effects , Treatment Outcome , Water Loss, Insensible/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL